W
William A. Carroll
Researcher at Abbott Laboratories
Publications - 103
Citations - 3096
William A. Carroll is an academic researcher from Abbott Laboratories. The author has contributed to research in topics: Potassium channel & Receptor. The author has an hindex of 26, co-authored 103 publications receiving 2946 citations. Previous affiliations of William A. Carroll include G. D. Searle & Company & AbbVie.
Papers
More filters
Journal ArticleDOI
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat
Michael F. Jarvis,Prisca Honore,Char Chang Shieh,Mark L. Chapman,Shailen K. Joshi,Xu Feng Zhang,Michael E. Kort,William A. Carroll,Brian E. Marron,Robert N. Atkinson,James Thomas,Dong Liu,Michael J. Krambis,Yi Liu,Steve McGaraughty,Katharine L. Chu,Rosemarie Roeloffs,Chengmin Zhong,Joseph P. Mikusa,Gricelda Hernandez,Donna M. Gauvin,Carrie Wade,Chang Zhu,Madhavi Pai,Marc J. C. Scanio,Lei Shi,Irene Drizin,Robert J. Gregg,Mark A. Matulenko,Ahmed A. Hakeem,Michael L. Gross,Matthew D. Johnson,Kennan C. Marsh,P. Kay Wagoner,James P. Sullivan,Connie R. Faltynek,Douglas S. Krafte +36 more
TL;DR: A-803467 is found, a sodium channel blocker that potently blocks tetrodotoxin-resistant currents and the generation of spontaneous and electrically evoked action potentials in vitro in rat dorsal root ganglion neurons and produces significant antinociception in animal models of neuropathic and inflammatory pain.
Journal ArticleDOI
A-740003 [N-(1-{[(Cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a Novel and Selective P2X7 Receptor Antagonist, Dose-Dependently Reduces Neuropathic Pain in the Rat
Prisca Honore,Diana L. Donnelly-Roberts,Marian T. Namovic,Gin C. Hsieh,Chang Z. Zhu,Joe Mikusa,Gricelda Hernandez,Chengmin Zhong,Donna M. Gauvin,Prasant Chandran,Richard R. Harris,Arturo Perez Medrano,William A. Carroll,Kennan C. Marsh,James P. Sullivan,Connie R. Faltynek,Michael F. Jarvis +16 more
TL;DR: It is demonstrated that selective blockade of P2X7 receptors in vivo produces significant antinociception in animal models of neuropathic and inflammatory pain.
Journal ArticleDOI
Structure−Activity Relationship Studies on a Series of Novel, Substituted 1-Benzyl-5-phenyltetrazole P2X7 Antagonists
Derek W. Nelson,Robert J. Gregg,Michael E. Kort,Arturo Perez-Medrano,Voight Eric,Ying Wang,George K. Grayson,Marian T. Namovic,Diana L. Donnelly-Roberts,Wende Niforatos,Prisca Honore,Michael F. Jarvis,Connie R. Faltynek,William A. Carroll +13 more
TL;DR: 1-Benzyl-5-aryltetrazoles were discovered to be novel antagonists for the P2X(7) receptor and advanced to efficacy studies in a model of neuropathic pain where significant reversal of mechanical allodynia was observed at doses that did not affect motor coordination.
Journal ArticleDOI
P2X7-related modulation of pathological nociception in rats
Steve McGaraughty,K.L. Chu,Marian T. Namovic,Diana L. Donnelly-Roberts,R.R. Harris,X.-F. Zhang,Char-Chang Shieh,Carol T. Wismer,C.Z. Zhu,Donna M. Gauvin,A.C. Fabiyi,Prisca Honore,Robert J. Gregg,Michael E. Kort,D.W. Nelson,William A. Carroll,Kennan C. Marsh,Connie R. Faltynek,Michael F. Jarvis +18 more
TL;DR: ATP, acting through the P2X7 receptor, exerts a wide-ranging influence on spinal neuronal activity following a chronic injury and is likely mediated through immuno-neural interactions that affect the release of endogenous cytokines.